alexa Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Clinical Research

Clinical Research

Journal of Clinical and Experimental Transplantation

Author(s): Agopian VG, Morshedi MM, McWilliams J, HarlanderLocke MP, Markovic D,

Abstract Share this page

Abstract OBJECTIVES: To evaluate the rate, effect, and predictive factors of a complete pathologic response (cPR) in patients with hepatocellular carcinoma (HCC) undergoing locoregional therapy (LRT) before liver transplantation (LT). BACKGROUND: Eligible patients with HCC receive equal model for end-stage liver disease prioritization, despite variable risks of tumor progression, waitlist dropout, and posttransplant recurrence. Pretransplant LRT mitigates these risks by inducing tumor necrosis. METHODS: Comparisons were made among HCC recipients with cPR (n = 126) and without cPR (n = 375) receiving pre-LT LRT (1994-2013). Multivariable predictors of cPR were identified. RESULTS: Of 501 patients, 272, 148, and 81 received 1, 2, and 3 or more LRT treatments. The overall, recurrence-free, and disease-specific survival at 1-, 3-, and 5 years was 86\%, 71\%, 63\%; 84\%, 67\%, 60\%; and 97\%, 90\%, 87\%. Compared with recipients without cPR, cPR patients had significantly lower laboratory model for end-stage liver disease scores, pretransplant alpha fetoprotein, and cumulative tumor diameters; were more likely to have 1 lesion, tumors within Milan/University of California, San Francisco (UCSF) criteria, LRT that included ablation, and a favorable tumor response to LRT; and had superior 1-, 3-, and 5-year recurrence-free survival (92\%, 79\%, and 73\% vs 81\%, 63\%, and 56\%; P = 0.006) and disease-specific survival (100\%, 100\%, and 99\% vs 96\%, 89\%, and 86\%; P < 0.001) with only 1 cancer-specific death and fewer recurrences (2.4\% vs 15.2\%; P < 0.001). Multivariate predictors of cPR included a favorable post-LRT radiologic/alpha fetoprotein tumor response, longer time interval from LRT to LT, and lower model for end-stage liver disease score and maximum tumor diameter (C-statistic 0.75). CONCLUSIONS: Achieving cPR in patients with HCC receiving LRT strongly predicts tumor-free survival. Factors predicting cPR are identified, allowing for differential prioritization of HCC recipients based on their variable risks of post-LT recurrence. Improving LRT strategies to maximize cPR would enhance posttransplant cancer outcomes. This article was published in Ann Surg and referenced in Journal of Clinical and Experimental Transplantation

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 2nd International Conference on Clinical Pediatrics and Pediatric Surgery
    June 29-30, 2017 London, UK
  • 9th Asia Pacific Global Summit on Healthcare
    Kuala Lumpur, Malaysia
  • 2nd International Conference on Plastic and Aesthetic Surgery & Medicine
    July 27-28, 2017 Vancouver,Canada

  • 2nd International Conference on Anesthesia and Analgesia
    September 07-08, 2017 London, U.K
  • 21st International Conference on Clinical & Experimental Cardiology
    October 16-18, 2017 Chicago, USA

  • 10th World Congress on Stem Cell and Biobanking
    October 23-24, 2017 Osaka, Japan
  • 9th World Congress on Immunity, Inflammation and Immunotherapies
    November 02-03, 2017 Atlanta, Georgia, USA
  • 10th International Conference on Clinical & Experimental Ophthalmology
    November 21- 23, 2016 Dubai, UAE

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords